Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 Feb 2022
Historique:
received: 07 10 2021
revised: 15 11 2021
accepted: 24 11 2021
pubmed: 30 11 2021
medline: 27 1 2022
entrez: 29 11 2021
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR) is safe and feasible in patients with bicuspid aortic valve (BAV), but whether annular size may influence TAVR results in BAV patients remains unclear. We aimed at evaluating the impact of aortic annular size on procedural and clinical outcomes of BAV patients undergoing TAVR, as well as potential interactions between annular dimension and trans-catheter heart valve (THV) type (balloon-expandable (BEV) vs. self-expanding (SEV). BEAT is a multicenter registry of consecutive BAV stenosis undergoing TAVR. For this sub-study patients were classified according to annular dimension in small-annulus (area < 400 mm 45(15.5%) patients had small, 132(45.3%) medium, and 114(39.2%) large annuli. Compared with other groups, patients with large annuli were more frequently male, younger, with higher body mass index, larger aortic valve area, higher rate of moderate-severe calcification, lower mean trans-aortic valve gradient and lower left ventricular ejection fraction. In large-annuli SEVs were associated with a lower VARC-2 device success (75.9% vs. 90.6%, p = 0.049) driven by a higher rate of paravalvular valvular leak (PVL) compared to BEVs (20.7% vs. 1.2%, p < 0.001). However, no differences in clinical outcomes were observed according to annular size nor THV type. TAVR in BAV patients is feasible irrespective of annular size. However in patients with large aortic annulus SEVs were associated with a significantly higher rate of PVLs compared to BEVs.

Sections du résumé

BACKGROUND BACKGROUND
Transcatheter aortic valve replacement (TAVR) is safe and feasible in patients with bicuspid aortic valve (BAV), but whether annular size may influence TAVR results in BAV patients remains unclear. We aimed at evaluating the impact of aortic annular size on procedural and clinical outcomes of BAV patients undergoing TAVR, as well as potential interactions between annular dimension and trans-catheter heart valve (THV) type (balloon-expandable (BEV) vs. self-expanding (SEV).
METHODS METHODS
BEAT is a multicenter registry of consecutive BAV stenosis undergoing TAVR. For this sub-study patients were classified according to annular dimension in small-annulus (area < 400 mm
RESULTS RESULTS
45(15.5%) patients had small, 132(45.3%) medium, and 114(39.2%) large annuli. Compared with other groups, patients with large annuli were more frequently male, younger, with higher body mass index, larger aortic valve area, higher rate of moderate-severe calcification, lower mean trans-aortic valve gradient and lower left ventricular ejection fraction. In large-annuli SEVs were associated with a lower VARC-2 device success (75.9% vs. 90.6%, p = 0.049) driven by a higher rate of paravalvular valvular leak (PVL) compared to BEVs (20.7% vs. 1.2%, p < 0.001). However, no differences in clinical outcomes were observed according to annular size nor THV type.
CONCLUSIONS CONCLUSIONS
TAVR in BAV patients is feasible irrespective of annular size. However in patients with large aortic annulus SEVs were associated with a significantly higher rate of PVLs compared to BEVs.

Identifiants

pubmed: 34843819
pii: S0167-5273(21)01871-4
doi: 10.1016/j.ijcard.2021.11.055
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-38

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Elisabetta Moscarella (E)

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Antonio Mangieri (A)

Department of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, Milan, Italy; Humanitas Research Hospital IRCCS, Rozzano-Milan, Italy.

Francesco Giannini (F)

Department of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, Milan, Italy; Humanitas Research Hospital IRCCS, Rozzano-Milan, Italy.

Didier Tchetchè (D)

Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France.

Won-Keun Kim (WK)

Kerckhoff Heart Center, Department of Cardiology, Bad Nauheim, Germany.

Jan-Malte Sinning (JM)

Cardiology Department, University Hospital Bonn, Bonn, Germany.

Uri Landes (U)

Cardiology Department, Rabin Medical Center, Petah Tikva, Israel.

Ran Kornowski (R)

Cardiology Department, Rabin Medical Center, Petah Tikva, Israel.

Ole De Backer (O)

The Heart Center-Rigshospitalet, Copenhagen, Denmark.

Georg Nickenig (G)

Cardiology Department, University Hospital Bonn, Bonn, Germany.

Chiara De Biase (C)

Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France.

Lars Søndergaard (L)

The Heart Center-Rigshospitalet, Copenhagen, Denmark.

Federico De Marco (F)

Department of Cardiology, IRCCS Policlinico San Donato, Milan, Italy.

Francesco Bedogni (F)

Department of Cardiology, IRCCS Policlinico San Donato, Milan, Italy.

Marco Ancona (M)

San Raffaele Scientific Institute, Milan, Italy.

Matteo Montorfano (M)

San Raffaele Scientific Institute, Milan, Italy.

Damiano Regazzoli (D)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Giulio Stefanini (G)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.

Stefan Toggweiler (S)

Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland.

Corrado Tamburino (C)

Cardiology Division, CAST Policlinico Hospital, University of Catania, Catania, Italy.

Sebastiano Immè (S)

Centro Cuore Morgagni, Catania, Italy.

Giuseppe Tarantini (G)

Interventional Cardiology Unit, University of Padova, Italy.

Horst Sievert (H)

Cardiovascular Center Frankfurt, Frankfurt, Germany; Anglia Ruskin University, Chelmsford, United Kingdom.

Ulrich Schäfer (U)

UKE Hamburg, Hamburg, Germany.

Jörg Kempfert (J)

Deutsches Herzzentrum Berlin, Charité Universitätsmedizin, Berlin, Germany.

Jochen Wöehrle (J)

Ulm University, Ulm, Germany.

Azeem Latib (A)

Department of Cardiology, Montefiore Medical Center, New York, NY, United States of America; Division of Cardiology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Paolo Calabrò (P)

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Massimo Medda (M)

Clinical and Interventional Cardiology Unit, Istituto Clinico Sant'Ambrogio, Milan, Italy.

Maurizio Tespili (M)

Clinical and Interventional Cardiology Unit, Istituto Clinico Sant'Ambrogio, Milan, Italy.

Antonio Colombo (A)

Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France; EMO GVM Centro Cuore Columbus, Milan, Italy.

Alfonso Ielasi (A)

Clinical and Interventional Cardiology Unit, Istituto Clinico Sant'Ambrogio, Milan, Italy. Electronic address: alielasi@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH